Global Diabetic Foot Ulcers Treatment Market to Grow Steadily Through 2035.
Diabetic foot ulcers treatment market is expected to witness steady growth during the forecast period, driven by the rising prevalence of diabetes and its associated complications such as neuropathic, ischemic, and neuro-ischemic ulcers. Increasing demand for advanced wound care solutions, including wound care dressings, devices, and active therapies, is further supporting market expansion. Additionally, growing adoption of hospital-based and homecare treatment approaches, along with rising awareness about early diagnosis and ulcer management, is contributing to improved patient outcomes worldwide.
Browse the full report description of “Global Diabetic Foot Ulcers Treatment Market Size, Share & Trends Analysis, By Treatment Type (Wound Care Dressing, Wound Care Devices, Active Therapies, and Others), By Type of Ulcer (Neuropathic Ulcers, Ischemic Ulcers, and Neuro-Ischemic Ulcers), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), Forecast (2021-2027)” at OMR Global at https://www.omrglobal.com/industry-reports/diabetic-foot-ulcers-treatment-market
Regenerative and advanced wound care therapies segment is expected to account for a major market share in 2026
Regenerative and advanced wound care therapies are expected to hold a major market share in 2026, primarily due to the increasing adoption of biologics, cell-based therapies, and next-generation wound healing technologies for diabetic foot ulcer (DFU) management. Companies including MediWound and Convatec are actively expanding their advanced DFU treatment pipelines through clinical trials, regulatory approvals, and strategic collaborations focused on chronic wound care innovation. The growing preference for regenerative therapies, including tissue-engineered products, nitric oxide-generating dressings, and biologic skin substitutes, is a key factor driving segment demand. Increasing cases of chronic diabetic wounds, rising risk of infection and amputation, and the need for faster healing solutions are further accelerating adoption across hospitals and specialized wound care centers.
Advanced nitric oxide-based wound dressing technologies segment is expected to witness significant growth in 2026
Advanced nitric oxide-based wound dressing technologies are expected to witness significant growth in 2026, primarily due to rising demand for anti-infective and enhanced healing solutions for diabetic foot ulcers. Convatec received regulatory approval for its ConvaNiox™ nitric oxide-generating wound dressing technology in 2025 and is preparing for broader commercialization across major European markets in 2026. The increasing focus on infection prevention, improved oxygenation, and accelerated wound closure in chronic diabetic wounds is a major factor supporting market growth. These technologies are gaining traction as healthcare providers seek advanced treatment options capable of reducing healing time, hospitalization rates, and complications associated with severe diabetic ulcers.
Clinical-stage biologic and enzymatic debridement therapies segment is expected to expand rapidly in 2026
Clinical-stage biologic and enzymatic debridement therapies are expected to expand rapidly in 2026, driven by increasing investment in chronic wound management research and late-stage diabetic foot ulcer treatment programs. MediWound initiated the global Phase III VALUE trial for EscharEx® in 2025 and is preparing a dedicated diabetic foot ulcer Phase II/III study planned for 2026. The company has also established collaborations with major wound-care companies including Mölnlycke, Solventum, and MIMEDX to strengthen chronic wound treatment development. Growing clinical focus on selective enzymatic debridement, improved tissue regeneration, and non-surgical wound bed preparation is expected to further support adoption across advanced wound care settings.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404